PRIDE (CRFB002DDE21): Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation vs. laser photocoagulation alone in Proliferative Diabetic Retinopathy
Laufzeit: 01.01.2013 - 31.12.2018
imported
Kurzfassung
Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation
vs. laser photocoagulation alone in Proliferative Diabetic Retinopathy
